Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Risperdal for bipolar mania

Executive Summary

Janssen's Risperdal (risperidone) approved Dec. 4 for short-term treatment of bipolar mania, as monotherapy or in combination with lithium or valproate. J&J has committed to a long-term bipolar mania study as post-marketing commitment. Updated labeling adds diabetes class warning, removes warnings on QT prolongation. Lilly's Zyprexa (olanzapine) was the first atypical with a short-term bipolar mania indication; Zyprexa is "approvable" for bipolar maintenance (1"The Pink Sheet" Nov. 3, 2003, p. 26)...

You may also be interested in...



Quarterly Call Round-Up: Pfizer, GSK, Lilly Updates

Pfizer sees more savings from Pharmacia: Pfizer is now projecting "at least" $1 bil. in synergies from the Pharmacia acquisition in 2003, indicating that it expects to exceed its original target of $1 bil. in first-year savings...

Janssen US Net Drug Prices Declined 5.7% in 2020; J&J Pushes Rebate Reform

Janssen's net drug prices declined for the fourth year in a row in 2020, while list prices increased 3.8%, according to the company's drug pricing report.

Moderna COVID-19 Boosters Show Preclinical Efficacy Versus South African Variant

While preclinical data show boosters to MRNA-1273 can reduce the threat of viral variants, the biotech also told investors it sees no link between its vaccine and thrombotic episodes.

UsernamePublicRestriction

Register

PS042943

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel